Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MarketBeat.com, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Bluejay Diagnostics, Inc., all published on August 12, 2026.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention MarketBeat.com, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Bluejay Diagnostics, Inc., all published on August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bluejay Diagnostics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
A MarketBeat comparison finds NexGel beats Bluejay Diagnostics on 9 of 13 metrics, with a $2.00 target and 284.69% upside. The biotech lens highlights divergent risk profiles between a diagnostics platform and a biomaterials company.
Source: tickerreport.com · dailypolitical.com
Bluejay Diagnostics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
